Combination of Sitagliptin and Metformin Clinical Trial

TITLE:
Randomized, Active-comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus

PURPOSE:

• To assess the effect of the fixed-dose combination sitagliptin/metformin compared with the effect of pioglitazone on HbA1c at week 40
• To assess the HbA1c-lowering efficacy of treatment with sitagliptin
• To assess the safety and tolerability of sitagliptin and the fixed-dose combination sitagliptin/metformin

PHASE:
3

INSTITUTIONAL REVIEW BOARD:
Quorum

STATUS:
Closed

ELIGIBILITY:
Persons aged 18  to 78 years with type 2 diabetes mellitus who are not currently on antihyperglycemic agent in the last 3 months with inadequate glycemic control.

DURATION:
12 visits over 48 weeks

Prinicpal Investigator:
Jeffrey Bauman, MD

CONTACT:
Kelly Ritter, CCRC
908-277-8747